Assure Tech (Hangzhou) Co. Ltd. Class A
SSSE:68807528.73
CNY
-0.39
(-1.34%)
ISIN
CNE100004ZC0
Return %
Stock
S&P 500
1Y
-26.05
14.20
3Y
-26.63
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Shi Sheng Ling
- Full Time Employees
- 551
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Building 4 Hangzhou ZH China 310011
- IPO Date
- Nov 18, 2021
- Website
- diareagent.com
- Similar Companies
- Business
- Assure Tech (Hangzhou) Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic (IVD) reagents, point-of-care testing (POCT) reagents, and related biological materials. The company’s core product portfolio includes immunochromatographic test reagents and analyzers, dry biochemical detection reagents, chemiluminescence test reagents and analyzers, nucleic acid test reagents and analyzers, and veterinary diagnostic products. Its diagnostic test offerings cover a wide range of categories such as drug of abuse tests, infectious disease tests, fertility tests, tumor marker tests, cardiac marker tests, biochemical tests, allergy tests, and chronic disease series. Assure Tech also manufactures clinical analytical instruments including fluorescence immunoassay analyzers and multi-monitoring systems for various biomarkers. The company operates with a global footprint, marketing its products both domestically in China and internationally. Founded in 2008 and headquartered in Hangzhou, China, Assure Tech focuses on biotechnology and healthcare sectors with specialized expertise in POCT and IVD technologies. In recent developments within the last two years, Assure Tech has strategically launched new fluorescent diagnostic products that combine advanced fluorescence immunoassay technology with rapid testing capabilities, attracting industry attention. The company has also made strides in expanding its product lines to include more quantitative chemiluminescence immunoassay reagents and bioactive materials. Assure Tech maintains robust R&D efforts to support innovation across its test kits and analyzers, positioning itself strongly in emerging digital and automated diagnostic solutions. The company is publicly listed on the Shanghai Stock Exchange STAR Market under ticker 688075.SS. The latest operational focus includes broadening its infectious disease test portfolio and chronic disease-related diagnostics, complemented by continuous enhancement of its analyzer platforms for usability and accuracy improvements. Assure Tech’s customer base spans hospitals, laboratories, veterinary clinics, emergency responders, and law enforcement agencies targeting clinical, point-of-care, and field testing environments. The company’s sustained commitment to quality and innovation is bolstered by certifications including US FDA 510(k) clearance for multiple products and recognition as a high-tech biotechnology enterprise in China. Assure Tech’s comprehensive product suite and recent innovations reflect its strategic intent to lead in the immunoassay and rapid diagnostic reagent markets, leveraging fluorescence and molecular diagnostic technologies. Its international sales growth alongside domestic market penetration underscores a balanced geographic focus. The company’s operational headquarters is located at Building 4, No. 1418-50 Moganshan Road, Gongshu District, Hangzhou, Zhejiang Province, China. In summary, Assure Tech (Hangzhou) Co., Ltd. operates as an advanced biotechnology company specializing in the manufacture and global distribution of diagnostic reagents and analytical instruments, emphasizing POCT solutions, fluorescent immunoassays, and molecular diagnostics, with recent product launches marking significant technological upgrades and market expansion.